Alumis Email Formats

Biotechnology Research • South San Francisco, California, United States • 201-500 Employees

Alumis Email Formats

Alumis uses 4 email formats. The most common is {first name}{last name} (e.g., johndoe@alumis.com), used 89.6% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@alumis.com	89.6%
{first initial}{last name}	jdoe@alumis.co	8.6%
{last name}{last name}	doedoe@alumis.co	1.2%

Key Contacts at Alumis

Yuri Klyachkin

Senior Director, Medical Affairs

Kim Burson

Senior Director Quality Operations

Victoria Moisa

Senior Director, People & Culture

Rachel Coker

Head Of Procurement Sr. Director

Zhengbin Yao

Member Board Of Directors

Jennifer Willetts

National Director, Field Medical

Yan Chang

Director

William Coble

Director, Quality Intelligence & Systems

Steve Antonie

Director, Hr Business Partner

Pedro Corpuz

Director Of Biomarker Operations

Company overview

Headquarters	611 Gateway Blvd, Suite 820, South San Francisco, California 94080, US
Phone number	+16502316625
Websites	alumis.com eskertx.com
NAICS	541714
Founded	2021
Employees	201-500
Socials

About Alumis

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.